Evaluation Questions

1. MJ is a 59-year-old male with T3b N2c M0 malignant melanoma on the left upper back, who underwent wide local excision of his primary and left axillary sentinel lymph node biopsy and resection of 1 positive lymph node. Mutation testing is negative for a BRAF V600 mutation but shows he has an NRAS mutation. After meeting with his medical oncologist, adjuvant pembrolizumab 200 mg intravenous (IV) every 3 weeks (Q3W) is initiated. MJ works part time from home and is a full-time caregiver for his spouse, who has amyotrophic lateral sclerosis (ALS). After 4 cycles, he meets with his oncologist again and has expressed difficulty with making it in regularly for appointments, labs, and pembrolizumab infusions. He is tolerating treatment well, and review of systems and laboratory analysis does not indicate immune-mediated adverse effects. What is the best option to allow MJ to remain on adjuvant therapy?

2. Based on studies that have been conducted comparing IV and SC dose formulations of monoclonal antibodies for certain oncologic malignancies, which of the following rationales supporting SC administration is NOT accurate?

3. Which of the following is a feature of the CheckMate 67T trial?

4. AB is a 62-year-old patient (92 kg) with multiple relapsed metastatic non-small cell lung cancer (NSCLC) and negative for EGFR and MET mutations. AB presents to interdisciplinary clinic to discuss next steps in care. Which of the following experimental arms, assuming all trials are open for enrollment, would be the most appropriate?

5. Which of the following is an important consideration when adopting SC immunotherapy in clinical practice?